Skip to main content
    E

    Estrella Immunopharma Inc. (ESLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.38
    -0.03 (-8.49%)

    Market Cap: $17.84M

    Last updated: Nov 06, 2026 at 4:04 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    75%(6/8)
    Avg Surprise
    +29.82%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.08
    Range$-0.08 - $-0.08
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$-0.080.0%
    7d ago$-0.080.0%
    Current$-0.08
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.00
    Range$0.00 - $0.00
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Last 12 of 21 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$0.00$0.00 - $0.00--1--
    Sep 26EST
    		-$-0.08$-0.08 - $-0.08--1
    1
    0
    30d
    		-
    Jun 26
    Reported Aug 13
    		$-0.05$-0.09$-0.09 - $-0.09+44.44%Beat1
    1
    0
    30d
    		+66.7%
    Mar 26
    Reported May 15
    		$-0.05N/A-+73.68%Beat1
    1
    0
    30d
    		+16.7%
    Dec 25
    Reported Mar 18
    		$-0.01N/A-+85.71%Beat1
    No revisions (30d)
    		+66.7%
    Sep 25
    Reported Nov 12
    		$-0.13$-0.07$-0.07 - $-0.07-85.71%Miss1
    No revisions (30d)
    		-44.4%
    Jun 25
    Reported Aug 11
    		$-0.15$-0.12$-0.12 - $-0.12-25.00%Miss1
    No revisions (30d)
    		-39.0%
    Mar 25
    Reported May 14
    		$-0.06$-0.11$-0.11 - $-0.11+45.45%Beat1
    No revisions (30d)
    		-354.5%
    Dec 24
    Reported Feb 15
    		$-0.03N/A-+75.00%Beat---3.4%
    Sep 24
    Reported Nov 14
    		$-0.09$-0.12-+25.00%Beat--+94.9%
    Jun 24
    Reported Sep 27
    		$-0.11N/A-N/ABeat---231.0%
    Mar 24
    Reported May 14
    		$-0.01N/A-N/ABeat--+51.5%
    Dec 23
    Reported Feb 14
    		$-0.03N/A-N/ABeat--+73.6%
    Sep 23
    Reported Sep 30
    		$-1.78N/A-N/ABeat---2861.5%

    Key Metrics

    Valuation
    P/E Ratio-1.56EV/EBITDAN/A
    Price/FCF-1.72xFCF Yield-58.15%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-268.50%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio0.20xQuick Ratio0.20x
    Trading Statistics
    Beta0.89Avg Volume5.18M
    52-Week High$3.0052-Week Low$0.24

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.61
    SMA 20$0.55
    SMA 50$0.55
    SMA 200$0.98
    EMA 10$0.52
    EMA 20$0.55
    EMA 50$0.58
    EMA 200$0.89

    MACD

    Line: -0.02Signal: 0.02Hist: -0.04

    ADX

    ADX: 30.8+DI: 28.1-DI: 29.0

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down44.0
    PSAR$1.10

    Bollinger Bands

    Upper Band$1.00
    Lower Band$0.11
    %B Position16014%(Upper)
    Band Width0.30

    RSI (14-Day)

    Neutral
    40.1

    Momentum Oscillators

    Stoch %K15.4
    Stoch %D18.8
    Williams %R-94.9
    ROC (10d)-61.9%
    Momentum-0.61
    CCI (20d)-57.6
    MFI (14d)88.0

    Volatility Measures

    ATR (14d)$0.13(34.7%)
    StdDev (20d)0.22
    Hist Vol382.2%(High)

    Volume Flow

    VWAP$0.40
    OBV51.5M
    AD Line649.0K
    CMF (20d)-0.030

    Volume Metrics

    Avg Vol (20d)4.7M
    Vol Ratio0.0x(Low)
    VWMA (20d)$0.57

    Pivot Points

    R3$0.48
    R2$0.46
    R1$0.44
    Pivot Point$0.42
    S1$0.39
    S2$0.37
    S3$0.35

    Advanced Oscillators

    TSI-3.66
    Ultimate Osc31.3
    KST287.70

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0N/A$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Gross ProfitN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Operating Expenses$2.08M$2.29M$613,199$4.80M$5.54M$2.10M$1.05M$3.38M$3.95M$469,530$1.02M$1.87M
    R&D$1.40M$1.40M$25,414$4.15M$4.66M$1.41M$32,566$2.83M$3.52M$25,000$75,459$483,466
    SG&A$684,015$891,789$587,785$648,507$883,727$694,110$1.02M$550,737$424,447$444,530$945,165$1.39M
    Operating Income$-2,084,247$-2,292,064$-613,199$-4,801,149$-5,544,028$-2,104,298$-1,050,227$-3,376,737$-3,949,447$-469,530$-1,020,624$-1,870,497
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$222,092$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-2,306,339$-2,292,064$-613,199$-4,801,149$-5,544,028$-2,104,298$-1,050,227$-3,376,737$-3,949,447$-469,530$-1,020,624$-1,870,497
    Income Tax Expense$0$0$-25$0$850$13$63$1,625$1,625$39,586$-122,089$-41,581
    Net Income$-2,306,339$-2,292,064$-613,174$-4,801,149$-5,544,878$-2,104,311$-1,050,290$-3,376,737$-3,951,072$-469,530$-1,020,624$-1,870,497
    EBITDA$-2,084,247$-2,292,064$-613,199$-4,801,149$-5,544,028$-2,104,298$-1,050,227$-3,376,737$-3,949,447$-469,530$-898,539$-1,828,913
    EBIT$-2,084,247$-2,292,064$-613,199$-4,801,149$-5,544,028$-2,104,298$-1,050,227$-3,376,737$-3,949,447$-429,944$-1,020,624$-1,870,497
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ESLA

    News

    Form 4 Estrella Immunopharma Inc: Cynthia Pussinen (Director, CEO) For: 2 November

    This article reports on a Form 4 filing for Estrella Immunopharma Inc, indicating that Cynthia Pussinen, in her roles as Director and CEO...

    Investing.com Canada•11/4/26•Neutral

    No securities ownership is reported by Estrella Immunopharma (ESLA) CEO and director Cynthia Pussinen.

    Estrella Immunopharma, Inc. (ESLA) CEO and director Cynthia Pussinen has filed an initial statement of beneficial ownership of securities (Form 3), reporting no beneficial ownership of ESLA securities. The filing...

    Stock Titan•11/3/26•Neutral

    Weekly Recap: Pussinen named CEO and chair and EB103 advancement

    Estrella Immunopharma, Inc. (NASDAQ:ESLA) has appointed Cynthia Pussinen as CEO and board chair, effective October 25, 2026...

    TradingView•11/3/26•Bullish

    Which four stocks lost up to 51% with thin cash, rising share counts and no confirmed catalyst on November 2: Change Agents Corporation (NASDAQ:CHGA), Estrella Immunopharma (NASDAQ:ESLA), Jaguar Health (NASDAQ:JAGX) and JIADE Limited (NASDAQ:JDZG)?

    This article examines four stocks—JIADE Limited (JDZG), Jaguar Health (JAGX), Estrella Immunopharma (ESLA), and Change Agents Corporation (CHGA)—that experienced significant losses of up to 51% on November 2...

    kalkine.ca•11/2/26•Bearish

    Estrella Immunopharma names Cynthia Pussinen as CEO and board chair

    Estrella Immunopharma (NASDAQ:ESLA) has appointed Cynthia Pussinen as its new CEO and Chairperson of the Board, effective October 25, amidst challenging financial conditions. Cheng Liu, Ph.D....

    Investing.com•10/29/26•Somewhat-Bearish

    ESLA Valuation and Fair Value

    P/E
    -1.6x
    P/FCF
    -1.7x
    P/B
    -2.2x
    See GNG's fair value

    ESLA Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -268.5%
    FCF yield
    -58.1%

    ESLA Competitors

    CompanyTicker
    Sensei Biotherapeutics IncSNSE
    Pasithea Therapeutics CorpKTTA
    Picard Medical, Inc.PMI
    Context Therapeutics IncCNTX
    Vyne Therapeutics IncVYNE
    Jasper Therapeutics IncJSPR
    Cocrystal Pharma IncCOCP
    Retractable Technologies IncRVP

    Sector: Healthcare

    ESLA Bull Case vs Bear Case

    Bull case

    • ESLA beat EPS estimates in 75.0% of its last 8 reported quarters.

    ESLA Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    29.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.08
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    ESLA Earnings Date

    ESLA reports Nov 10, 2026. The date is estimated.

    ESLA ETF Holders

    GNG tracks 2 ETFs that hold ESLA. The largest weights:

    1. Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
    2. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    Open the ETF Stock Exposure tool for ESLA

    Frequently Asked Questions About ESLA

    When does ESLA report earnings?

    Estrella Immunopharma Inc. (ESLA) is expected to report earnings on Nov 10, 2026.

    Does ESLA pay dividends?

    Estrella Immunopharma Inc. (ESLA) does not currently pay a regular dividend.

    What is ESLA's market cap?

    Estrella Immunopharma Inc. (ESLA) has a market capitalization of $17.84M with a current stock price of $0.38.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In